<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Biffi, Alessandro</style></author><author><style face="normal" font="default" size="100%">Urday, Sebastian</style></author><author><style face="normal" font="default" size="100%">Kubiszewski, Patryk</style></author><author><style face="normal" font="default" size="100%">Gilkerson, Lee</style></author><author><style face="normal" font="default" size="100%">Sekar, Padmini</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Torres, Axana</style></author><author><style face="normal" font="default" size="100%">Bettin, Margaret</style></author><author><style face="normal" font="default" size="100%">Charidimou, Andreas</style></author><author><style face="normal" font="default" size="100%">Pasi, Marco</style></author><author><style face="normal" font="default" size="100%">Kourkoulis, Christina</style></author><author><style face="normal" font="default" size="100%">Schwab, Kristin</style></author><author><style face="normal" font="default" size="100%">DiPucchio, Zora</style></author><author><style face="normal" font="default" size="100%">Behymer, Tyler</style></author><author><style face="normal" font="default" size="100%">Osborne, Jennifer</style></author><author><style face="normal" font="default" size="100%">Morgan, Misty</style></author><author><style face="normal" font="default" size="100%">Moomaw, Charles J</style></author><author><style face="normal" font="default" size="100%">James, Michael L</style></author><author><style face="normal" font="default" size="100%">Greenberg, Steven M</style></author><author><style face="normal" font="default" size="100%">Viswanathan, Anand</style></author><author><style face="normal" font="default" size="100%">Gurol, M Edip</style></author><author><style face="normal" font="default" size="100%">Worrall, Bradford B</style></author><author><style face="normal" font="default" size="100%">Testai, Fernando D</style></author><author><style face="normal" font="default" size="100%">McCauley, Jacob L</style></author><author><style face="normal" font="default" size="100%">Falcone, Guido J</style></author><author><style face="normal" font="default" size="100%">Langefeld, Carl D</style></author><author><style face="normal" font="default" size="100%">Anderson, Christopher D</style></author><author><style face="normal" font="default" size="100%">Kamel, Hooman</style></author><author><style face="normal" font="default" size="100%">Woo, Daniel</style></author><author><style face="normal" font="default" size="100%">Sheth, Kevin N</style></author><author><style face="normal" font="default" size="100%">Rosand, Jonathan</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Combining Imaging and Genetics to Predict Recurrence of Anticoagulation-Associated Intracerebral Hemorrhage.</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Anticoagulants</style></keyword><keyword><style  face="normal" font="default" size="100%">Apolipoprotein E4</style></keyword><keyword><style  face="normal" font="default" size="100%">Cerebral Hemorrhage</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Magnetic Resonance Imaging</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Neuroimaging</style></keyword><keyword><style  face="normal" font="default" size="100%">Recurrence</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020 07</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">51</style></volume><pages><style face="normal" font="default" size="100%">2153-2160</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND AND PURPOSE: &lt;/b&gt;For survivors of oral anticoagulation therapy (OAT)-associated intracerebral hemorrhage (OAT-ICH) who are at high risk for thromboembolism, the benefits of OAT resumption must be weighed against increased risk of recurrent hemorrhagic stroke. The ε2/ε4 alleles of the  () gene, MRI-defined cortical superficial siderosis, and cerebral microbleeds are the most potent risk factors for recurrent ICH. We sought to determine whether combining MRI markers and  genotype could have clinical impact by identifying ICH survivors in whom the risks of OAT resumption are highest.&lt;/p&gt;&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;Joint analysis of data from 2 longitudinal cohort studies of OAT-ICH survivors: (1) MGH-ICH study (Massachusetts General Hospital ICH) and (2) longitudinal component of the ERICH study (Ethnic/Racial Variations of Intracerebral Hemorrhage). We evaluated whether MRI markers and  genotype predict ICH recurrence. We then developed and validated a combined -MRI classification scheme to predict ICH recurrence, using Classification and Regression Tree analysis.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;Cortical superficial siderosis, cerebral microbleed, and  ε2/ε4 variants were independently associated with ICH recurrence after OAT-ICH (all &lt;0.05). Combining  genotype and MRI data resulted in improved prediction of ICH recurrence (Harrell C: 0.79 versus 0.55 for clinical data alone, =0.033). In the MGH (training) data set, CSS, cerebral microbleed, and  ε2/ε4 stratified likelihood of ICH recurrence into high-, medium-, and low-risk categories. In the ERICH (validation) data set, yearly ICH recurrence rates for high-, medium-, and low-risk individuals were 6.6%, 2.5%, and 0.9%, respectively, with overall area under the curve of 0.91 for prediction of recurrent ICH.&lt;/p&gt;&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;Combining MRI and  genotype stratifies likelihood of ICH recurrence into high, medium, and low risk. If confirmed in prospective studies, this combined -MRI classification scheme may prove useful for selecting individuals for OAT resumption after ICH.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">7</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32517581?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Leasure, Audrey C</style></author><author><style face="normal" font="default" size="100%">Sheth, Kevin N</style></author><author><style face="normal" font="default" size="100%">Comeau, Mary</style></author><author><style face="normal" font="default" size="100%">Aldridge, Chad</style></author><author><style face="normal" font="default" size="100%">Worrall, Bradford B</style></author><author><style face="normal" font="default" size="100%">Vashkevich, Anastasia</style></author><author><style face="normal" font="default" size="100%">Rosand, Jonathan</style></author><author><style face="normal" font="default" size="100%">Langefeld, Carl</style></author><author><style face="normal" font="default" size="100%">Moomaw, Charles J</style></author><author><style face="normal" font="default" size="100%">Woo, Daniel</style></author><author><style face="normal" font="default" size="100%">Falcone, Guido J</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Identification and Validation of Hematoma Volume Cutoffs in Spontaneous, Supratentorial Deep Intracerebral Hemorrhage.</style></title><secondary-title><style face="normal" font="default" size="100%">Stroke</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stroke</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2019 Aug</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">50</style></volume><pages><style face="normal" font="default" size="100%">2044-2049</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Background and Purpose- Clinical trials in spontaneous intracerebral hemorrhage (ICH) have used volume cutoffs as inclusion criteria to select populations in which the effects of interventions are likely to be the greatest. However, optimal volume cutoffs for predicting poor outcome in deep locations (thalamus versus basal ganglia) are unknown. Methods- We conducted a 2-phase study to determine ICH volume cutoffs for poor outcome (modified Rankin Scale score of 4-6) in the thalamus and basal ganglia. Cutoffs with optimal sensitivity and specificity for poor outcome were identified in the ERICH ([Ethnic/Racial Variations of ICH] study; derivation cohort) using receiver operating characteristic curves. The cutoffs were then validated in the ATACH-2 trial (Antihypertensive Treatment of Acute Cerebral Hemorrhage-2) by comparing the c-statistic of regression models for outcome (including dichotomized volume) in the validation cohort. Results- Of the 3000 patients enrolled in ERICH, 1564 (52%) had deep ICH, of whom 1305 (84%) had complete neuroimaging and outcome data (660 thalamic and 645 basal ganglia hemorrhages). Receiver operating characteristic curve analysis identified 8 mL in thalamic (area under the curve, 0.79; sensitivity, 73%; specificity, 78%) and 18 mL in basal ganglia ICH (area under the curve, 0.79; sensitivity, 70%; specificity, 83%) as optimal cutoffs for predicting poor outcome. The validation cohort included 834 (84%) patients with deep ICH and complete neuroimaging data enrolled in ATACH-2 (353 thalamic and 431 basal ganglia hemorrhages). In thalamic ICH, the c-statistic of the multivariable outcome model including dichotomized ICH volume was 0.80 (95% CI, 0.75-0.85) in the validation cohort. For basal ganglia ICH, the c-statistic was 0.81 (95% CI, 0.76-0.85) in the validation cohort. Conclusions- Optimal hematoma volume cutoffs for predicting poor outcome in deep ICH vary by the specific deep brain nucleus involved. Utilization of location-specific volume cutoffs may improve clinical trial design by targeting deep ICH patients that will obtain maximal benefit from candidate therapies.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">8</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31238829?dopt=Abstract</style></custom1></record></records></xml>